Last updated on August 2018

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)

Brief description of study

This study will evaluate the efficacy, safety, and tolerability of rapastinel 450 mg compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) who have a partial response to ADT.

Clinical Study Identifier: NCT02932943

Contact Investigators or Research Sites near you

Start Over

Clinical Trials Registry Team

Meridien Research
Bradenton, FL United States
  Connect »